Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides
Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial.
Sponsor: University of Parma
Listed as NCT00751517, this PHASE2 trial focuses on Churg-Strauss Syndrome and Microscopic Polyangiitis and remains ongoing. Sponsored by University of Parma, it has been updated 4 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jan 2021 [monthly]
Unknown Status PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Parma
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Parma, Italy